J&J Falls as 4Q Revenue Misses Expectations

The transcript discusses the impact of a strong dollar on a major healthcare company's stock, strategic options for its diabetes care business, and a potential acquisition of a Swiss biotech firm. It highlights the company's financials, including its cash flow and the significance of its pharmaceuticals unit. The restructuring of its Medical Devices division and growth in consumer health are noted. The Actelion deal is expected to strengthen its drug business amid competition. The influence of political decisions on medicine costs is also mentioned.

What factors did the CFO mention that could affect the company's forecast?

What strategic options is Johnson & Johnson evaluating for its diabetes care business?

How much free cash flow did Johnson & Johnson estimate for the fiscal year 2016?

What percentage of sales in the fourth quarter did the pharmaceuticals unit account for?

What impact did President Trump promise to have on the cost of medicines?